TY - JOUR T1 - The Pan-Cancer Landscape of Prognostic Germline Variants in 10,582 Patients JF - medRxiv DO - 10.1101/19010264 SP - 19010264 AU - Ajay Chatrath AU - Roza Przanowska AU - Shashi Kiran AU - Zhangli Su AU - Shekhar Saha AU - Briana Wilson AU - Takaaki Tsunematsu AU - Ji-Hye Ahn AU - Kyung Yong Lee AU - Teressa Paulsen AU - Ewelina Sobierajska AU - Manjari Kiran AU - Xiwei Tang AU - Tianxi Li AU - Pankaj Kumar AU - Aakrosh Ratan AU - Anindya Dutta Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/10/29/19010264.abstract N2 - While clinical data provides physicians with information about patient prognosis, genomic data can further improve these predictions. We analyzed sequencing data from over 10,000 cancer patients and identified hundreds of prognostic germline variants using multivariate Cox regression models. These variants provide information about patient outcomes beyond clinical information currently in use and may augment clinical decisions based on expected tumor aggressiveness. Molecularly, at least twelve of the germline variants are likely associated with patient outcome through perturbation of protein structure and at least five through association with gene expression differences. About half of these germline variants are in previously reported tumor suppressors or oncogenes, with the other half pointing to loci of previously unstudied genes in the literature that should be further investigated for roles in cancers. Our results suggest that germline variation contributes to tumor progression across most cancers and contains patient outcome information not captured by clinical factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the NIH R01 CA166054, R01 CA60499, T32 GM007267 (AC, BW), AHA 18PRE33990261 (RP), and a Cancer Genomics Cloud Collaborative Support grant. The Seven Bridges Cancer Genomics Cloud has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Contract No. HHSN261201400008C and ID/IQ Agreement No. 17X146 under Contract No. HHSN261201500003I. Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesAll of the raw data from The Cancer Genome Atlas used in this analysis is publicly available from the genomic data commons (https://portal.gdc.cancer.gov/). https://portal.gdc.cancer.gov/ ER -